---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-017223"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:24:17.039420+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio Green Med Solution sells Plogosertib assets to Tethra Biosciences for $300K upfront plus $170K milestone

## Summary
- Sold all patent rights and IP related to Plogosertib (PLK1 inhibitor) to Tethra Biosciences Inc.
- Total consideration: $300,000 upfront plus a potential $170,000 milestone upon first patient dosing in Phase 2.
- Transaction closed on October 6, 2025, with customary representations and warranties.
- Buyer assumes obligations related to the Compound from closing forward; seller retains excluded liabilities.

## SEC filing metadata
- accession: 0001493152-25-017223
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000149315225017223/0001493152-25-017223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000149315225017223/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-017223
- JSON: https://secwatch.observer/filing/0001493152-25-017223.json
- Plain text: https://secwatch.observer/filing/0001493152-25-017223.txt

## Source-grounded claims
- claim_id: 2efba5a0068e2a0c47557659e2b54bb58f76ad09
  claim: Bio Green Med Solution, Inc. completed a disposition involving Tethra Biosciences Inc. for $300,000, plus a further potential Milestone of $170,000 (closed 2025-10-06).
  evidence_excerpt: of the Company related to Plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies (“Plogo”), for a purchase price of $300,000, plus a further potential Milestone (as defined in the Purchase Agreement) of $170,000. The Purchase Agreement contains customary representations, warranties and covenants. The
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000149315225017223/0001493152-25-017223-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.